1
|
Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy. Int J Mol Sci 2023; 24:ijms24032655. [PMID: 36768976 PMCID: PMC9916513 DOI: 10.3390/ijms24032655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 01/26/2023] [Accepted: 01/28/2023] [Indexed: 02/01/2023] Open
Abstract
Near infrared photoimmunotherapy (NIR-PIT) is a newly developed molecular targeted cancer treatment, which selectively kills cancer cells or immune-regulatory cells and induces therapeutic host immune responses by administrating a cancer targeting moiety conjugated with IRdye700. The local exposure to near-infrared (NIR) light causes a photo-induced ligand release reaction, which causes damage to the target cell, resulting in immunogenic cell death (ICD) with little or no side effect to the surrounding normal cells. Moreover, NIR-PIT can generate an immune response in distant metastases and inhibit further cancer attack by combing cancer cells targeting NIR-PIT and immune regulatory cells targeting NIR-PIT or other cancer treatment modalities. Several recent improvements in NIR-PIT have been explored such as catheter-driven NIR light delivery, real-time monitoring of cancer, and the development of new target molecule, leading to NIR-PIT being considered as a promising cancer therapy. In this review, we discuss the progress of NIR-PIT, their mechanism and design strategies for cancer treatment. Furthermore, the overall possible targeting molecules for NIR-PIT with their application for cancer treatment are briefly summarised.
Collapse
|
2
|
Le Gall CM, van der Schoot JMS, Ramos-Tomillero I, Khalily MP, van Dalen FJ, Wijfjes Z, Smeding L, van Dalen D, Cammarata A, Bonger KM, Figdor CG, Scheeren FA, Verdoes M. Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering. Bioconjug Chem 2021; 32:301-310. [PMID: 33476135 PMCID: PMC7898269 DOI: 10.1021/acs.bioconjchem.0c00673] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
![]()
Functionalized antibodies
and antibody fragments have found applications
in the fields of biomedical imaging, theranostics, and antibody–drug
conjugates (ADC). In addition, therapeutic and theranostic approaches
benefit from the possibility to deliver more than one type of cargo
to target cells, further challenging stochastic labeling strategies.
Thus, bioconjugation methods to reproducibly obtain defined homogeneous
conjugates bearing multiple different cargo molecules, without compromising
target affinity, are in demand. Here, we describe a straightforward
CRISPR/Cas9-based strategy to rapidly engineer hybridoma cells to
secrete Fab′ fragments bearing two distinct site-specific labeling
motifs, which can be separately modified by two different sortase
A mutants. We show that sequential genetic editing of the heavy chain
(HC) and light chain (LC) loci enables the generation of a stable
cell line that secretes a dual tagged Fab′ molecule (DTFab′),
which can be easily isolated. To demonstrate feasibility, we functionalized
the DTFab′ with two distinct cargos in a site-specific manner.
This technology platform will be valuable in the development of multimodal
imaging agents, theranostics, and next-generation ADCs.
Collapse
Affiliation(s)
- Camille M Le Gall
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Oncode Institute, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Johan M S van der Schoot
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Oncode Institute, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Iván Ramos-Tomillero
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, Netherlands
| | - Melek Parlak Khalily
- Department of Synthetic Organic Chemistry, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands
| | - Floris J van Dalen
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Zacharias Wijfjes
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, Netherlands
| | - Liyan Smeding
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Duco van Dalen
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Anna Cammarata
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands
| | - Kimberly M Bonger
- Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, Netherlands.,Department of Synthetic Organic Chemistry, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands
| | - Carl G Figdor
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Oncode Institute, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, Netherlands
| | - Ferenc A Scheeren
- Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Martijn Verdoes
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, The Netherlands.,Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, Netherlands
| |
Collapse
|
3
|
Macias-Contreras M, He H, Little KN, Lee JP, Campbell RP, Royzen M, Zhu L. SNAP/CLIP-Tags and Strain-Promoted Azide–Alkyne Cycloaddition (SPAAC)/Inverse Electron Demand Diels–Alder (IEDDA) for Intracellular Orthogonal/Bioorthogonal Labeling. Bioconjug Chem 2020; 31:1370-1381. [DOI: 10.1021/acs.bioconjchem.0c00107] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Miguel Macias-Contreras
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, United States
| | - Huan He
- Translational Science Laboratory, College of Medicine, Florida State University, Tallahassee, Florida 32306-4300, United States
- Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida 32306-4380, United States
| | - Kevin N. Little
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, United States
| | - Justin P. Lee
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, United States
| | - Ryan P. Campbell
- Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida 32306-4380, United States
| | - Maksim Royzen
- Department of Chemistry, University at Albany, 1400 Washington Avenue, Albany, New York 12222, United States
| | - Lei Zhu
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, United States
| |
Collapse
|
4
|
Xiao Q, Liu Z, Zhao X, Xiong H. Multiple Site-Specific One-Pot Synthesis of Two Proteins by the Bio-Orthogonal Flexizyme System. Front Bioeng Biotechnol 2020; 8:37. [PMID: 32117920 PMCID: PMC7010957 DOI: 10.3389/fbioe.2020.00037] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 01/15/2020] [Indexed: 11/29/2022] Open
Abstract
Lysine acetylation is a reversible post-translational modification (PTM) vastly employed in many biological events, including regulating gene expression and dynamic transitions in chromatin remodeling. We have developed the first one-pot bio-orthogonal flexizyme system in which both acetyl-lysine (AcK) and non-hydrolysable thioacetyl-lysine (ThioAcK) were site-specifically incorporated into human histone H3 and H4 at different lysine positions in vitro, either individually or in pairs. In addition, the high accuracy of this system moving toward one-pot synthesis of desired histone variants is also reported.
Collapse
Affiliation(s)
- Qiuyun Xiao
- Institute for Advanced Study, Shenzhen University, Shenzhen, China.,Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen, China
| | - Zihan Liu
- Institute for Advanced Study, Shenzhen University, Shenzhen, China
| | - Xuan Zhao
- Institute for Advanced Study, Shenzhen University, Shenzhen, China
| | - Hai Xiong
- Institute for Advanced Study, Shenzhen University, Shenzhen, China
| |
Collapse
|
6
|
Lee MD, Tong WY, Nebl T, Pearce LA, Pham TM, Golbaz-Hagh A, Puttick S, Rose S, Adams TE, Williams CC. Dual Site-Specific Labeling of an Antibody Fragment through Sortase A and π-Clamp Conjugation. Bioconjug Chem 2019; 30:2539-2543. [DOI: 10.1021/acs.bioconjchem.9b00639] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Michael D. Lee
- CSIRO Manufacturing, Parkville, Victoria 3052, Australia
| | - Wing Yin Tong
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Thomas Nebl
- CSIRO Manufacturing, Parkville, Victoria 3052, Australia
| | | | - Tam M. Pham
- CSIRO Manufacturing, Parkville, Victoria 3052, Australia
| | - Arghavan Golbaz-Hagh
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St. Lucia, 4072, Australia
| | - Simon Puttick
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St. Lucia, 4072, Australia
- CSIRO Health and Biosecurity, Herston, Queensland 4029, Australia
| | - Stephen Rose
- CSIRO Health and Biosecurity, Herston, Queensland 4029, Australia
| | | | | |
Collapse
|
7
|
Thornlow DN, Cox EC, Walker JA, Sorkin M, Plesset JB, DeLisa MP, Alabi CA. Dual Site-Specific Antibody Conjugates for Sequential and Orthogonal Cargo Release. Bioconjug Chem 2019; 30:1702-1710. [PMID: 31083974 DOI: 10.1021/acs.bioconjchem.9b00244] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Antibody-drug conjugates utilize the antigen specificity of antibodies and the potency of chemotherapeutic and antibiotic drugs for targeted therapy. However, as cancers and bacteria evolve to resist the action of drugs, innovative controlled release methods must be engineered to deliver multidrug cocktails. In this work, we engineer lipoate-acid ligase A (LplA) acceptor peptide (LAP) tags into the constant heavy and light chain of a humanized Her2 targeted antibody, trastuzumab. These engineered LAP tags, along with the glutamine 295 (Q295) residue in the heavy chain, were used to generate orthogonally cleavable site-specific antibody conjugates via a one-pot chemoenzymatic ligation with microbial transglutaminase (mTG) and LplA. We demonstrate orthogonal cargo release from these dual-labeled antibody bioconjugates via matrix metalloproteinase-2 and cathepsin-B-mediated bond cleavage. To the best of our knowledge, this is the first demonstration of temporal control on dual-labeled antibody conjugates, and we believe this platform will allow for sequential release and cooperative drug combinations on a single antibody bioconjugate.
Collapse
Affiliation(s)
- Dana N Thornlow
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Emily C Cox
- Biological and Biomedical Sciences , Cornell University College of Veterinary Medicine , Ithaca , New York 14853 , United States
| | - Joshua A Walker
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Michelle Sorkin
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Jacqueline B Plesset
- Meinig School of Biomedical Engineering , Cornell University , Ithaca , New York 14853 , United States
| | - Matthew P DeLisa
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Christopher A Alabi
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| |
Collapse
|